ArticleCurrent infectious disease reports2008
The molecular pathogenesis of Clostridium difficile-associated disease.
Article in Current infectious disease reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.Current infectious disease reports · 2011Article
- Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells.Gut pathogens · 2009Article
- Clostridium difficile toxin A promotes dendritic cell maturation and chemokine CXCL2 expression through p38, IKK, and the NF-kappaB signaling pathway.Journal of molecular medicine (Berlin, Germany) · 2009Article
- Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?Bone marrow transplantation · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile-associated disease is a reemerging nosocomial disease of paramount importance not only in the United States, but most of the world as well. Recently, C. difficile-associated disease appears to be on the rise, with a parallel increase noted in its severity and extent. Although the main virulence factors, the large exotoxins known as toxin A and toxin B, have long been identified, only in the past few years has a near explosion of new information regarding the details of the toxin-mediated pathogenicity come to light. This update gives an overview of some of the more exciting and insightful reports published in the recent literature.
Identifiers
18462584What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.